Market Place
Sourcing Support
Idorsia in Exclusive Talks for Global Rights to Aprocitentan
27 Nov 2024 //
GLOBENEWSWIRE
Idorsia’s Tryvio Available for Difficult-to-Control Hypertension
15 Nov 2024 //
PR NEWSWIRE
New Data On Aprocitentan To Be Presented At Hypertension Sessions
05 Sep 2024 //
GLOBENEWSWIRE
EU regulator clears Idorsia’s Jeraygo to resistant hypertension
02 Jul 2024 //
PRESS RELEASE
Idorsia’s Aprocitentan Approved in Europe, First ERA For Resistant Hypertension
01 Jul 2024 //
GLOBENEWSWIRE
Aprocitentan PRECISION Data At European Hypertension Congress 2024
30 May 2024 //
GLOBENEWSWIRE
JERAYGO (aprocitentan) Recommended for EU Approval in Resistant HTN
26 Apr 2024 //
GLOBENEWSWIRE
US FDA approves Idorsia`s once-daily TRYVIO (aprocitentan)
21 Mar 2024 //
PRESS RELEASE
US FDA approves TRYVIO (aprocitentan) for the treatment of high blood pressure
20 Mar 2024 //
PR NEWSWIRE
J&J pulls out of Idorsia deal for hypertension drug
07 Sep 2023 //
PHARMAPHORUM
New Phase 3 data with aprocitentan has been presented
26 Jun 2023 //
GLOBENEWSWIRE
Idorsia submits a NDA to the US FDA for aprocitentan
20 Dec 2022 //
GLOBENEWSWIRE
Idorsia submits a new drug application to the FDA
20 Dec 2022 //
REUTERS
The Lancet & AHA late-breaking session reports significant & effect aprocitentan
07 Nov 2022 //
GLOBENEWSWIRE
Invitation to Idorsia`s webcast and conference call
03 Nov 2022 //
GLOBENEWSWIRE
Idorsia claims PhIII win for hypertension drug at center of $230M J&J deal
24 May 2022 //
ENDPTS
Positive PIII study with aprocitentan shows significant anti HTN efficacy
23 May 2022 //
GLOBENEWSWIRE
Little Idorsia Scores $230M+ R&D Deal With Johnson & Johnson
04 Dec 2017 //
BIOSPACE
Idorsia spins out of Actelion with $1B and multidrug pipeline
17 Jun 2016 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.